| Mycobacterium monacense |
Taxonomy
Morphology
Cultural characteristics
Biochemical characters
Ecology
Pathogenicity
References
Phylum Actinobacteria, Class Actinobacteria, Order Actinomycetales, Suborder Corynebacterineae, Family Mycobacteriaceae, Genus
Mycobacterium, Mycobacterium monacense Reischl et al. 2006.
Mycobacterium, Mycobacterium monacense Reischl et al. 2006.
Acid-fast rods. Gram-positive. Non-motile. Non-spore-forming.
Colonies are smooth, yellow, scotochromogenic and growing within 7 days at 25-45
ºC. Can grow on Lowenstein-Jensen supplemented with 5% NaCl. No growth on
MacConkey agar without crystal violet.
ºC. Can grow on Lowenstein-Jensen supplemented with 5% NaCl. No growth on
MacConkey agar without crystal violet.
Undetermined. May be involved in chronic pulmonary disease.
Isolated from clinical specimens (bronchial lavage, wound infection, sputum) in United States, Germany, India and Iran.
Susceptible to amikacin, cefoxitin, ciprofloxacin, clarithromycin, doxycycline and linezolid. The iranian isolate was susceptible to
amikacin (≤1 µg/ml), cefoxitin (2 µg/ml), ciprofloxacin (≤0.12 µg/ml), clarithromycin (≤0.12 µg/ml), doxicyclin (≤1 µg/ml), ethambutol (≤0.
5 µg/ml), imipenem (1 µg/ml), rifampicin (≤0.06 µg/ml), streptomycin (2 µg/ml), and sulfamethoxazol (1 µg/ml). The indian isolate was
susceptible to to streptomycin, isoniazid, rifampicin, ethambutol, pyrazinamide, cefoxitin, doxycycline, amikacin, azithromycin,
tobramycin, clarithromycin, ciprofloxacin, ofloxacin, norfloxacin, gatifloxacin and moxifloxacin.
Susceptible to amikacin, cefoxitin, ciprofloxacin, clarithromycin, doxycycline and linezolid. The iranian isolate was susceptible to
amikacin (≤1 µg/ml), cefoxitin (2 µg/ml), ciprofloxacin (≤0.12 µg/ml), clarithromycin (≤0.12 µg/ml), doxicyclin (≤1 µg/ml), ethambutol (≤0.
5 µg/ml), imipenem (1 µg/ml), rifampicin (≤0.06 µg/ml), streptomycin (2 µg/ml), and sulfamethoxazol (1 µg/ml). The indian isolate was
susceptible to to streptomycin, isoniazid, rifampicin, ethambutol, pyrazinamide, cefoxitin, doxycycline, amikacin, azithromycin,
tobramycin, clarithromycin, ciprofloxacin, ofloxacin, norfloxacin, gatifloxacin and moxifloxacin.
- Reischl U, Melzl H, Kroppenstedt RM, Miethke T, Naumann L, Mariottini A, Mazzarelli G, Tortoli E. Mycobacterium monacense sp.
nov. Int J Syst Evol Microbiol 2006; 56:2575-2578. - Shojaei H, Hashemi A, Heidarieh P, Hosseini N, Daei Naser A. Chronic pulmonary disease due to Mycobacterium monacense
infection: the first case from Iran. Ann Lab Med. 2012;32(1):87-90. doi:10.3343/alm.2012.32.1.87. - . Therese KL, Gayathri R, Thiruppathi K, Madhavan HN. First report on isolation of Mycobacterium monacense from sputum
specimen in India. Lung India 2011;28:124-6. - John G. Magee and Alan C. Ward 2012. Family III. Mycobacteriaceae Chester 1897, 63AL in Bergey’s Manual of Systematic
Bacteriology, Volume Five The Actinobacteria, Part A, Michael Goodfellow & al. (editors), 312-375.
Positive results for thermostable catalase (68 ºC) nitrate reduction, tellurite reduction,
and Tween 80 hydrolysis.
Negative results for arylsulfatase (3 and 14 days), beta-glucosidase, and niacin accumulation.
Variable results for semiquantitative catalase, iron uptake, and urea hydrolysis.
and Tween 80 hydrolysis.
Negative results for arylsulfatase (3 and 14 days), beta-glucosidase, and niacin accumulation.
Variable results for semiquantitative catalase, iron uptake, and urea hydrolysis.
(c) Costin Stoica
| Antibiogram |
| Encyclopedia |
| Culture media |
| Biochemical tests |
| Stainings |
| Images |
| Movies |
| Articles |
| Identification |
| Software |
| R E G N U M PROKARYOTAE |
| Back |
